Skip to main content
Log in

Spleen stiffness measurement for assessing the response to β-blockers therapy for high-risk esophageal varices patients

  • Original Article
  • Published:
Hepatology International Aims and scope Submit manuscript

Abstract

Background

Non-selective β-blocker (NSBB) therapy is the treatment of choice for primary prophylaxis of cirrhotic patients with high-bleeding risk esophageal varices (HRV). The hemodynamic response to NSBB is assessed by the measurement of the hepatic venous pressure gradient (HVPG). Recently, liver and spleen stiffness measurements (LSM and SSM) were proposed as non-invasive surrogates of HVPG. We aimed to evaluate LSM and SSM changes for assessing hemodynamic response in these patients.

Methods

Cirrhotic patients with HRV were prospectively enrolled and evaluated at our Department before starting NSBB and after 3 months. Correlation between changes (delta) of HVPG after NSBB treatment and those of LSM or SSM by transient elastography was performed.

Results

From the initial 59 patients considered for the study, 20 were finally included in the analysis. Fifteen (15) patients reached hemodynamic response to NSBB according to HVPG. Changes in LSM did not correlate with changes in HVPG (r = 0.107, p value = 0.655), unlike changes in SSM (r = 0.784, p value < 0.0001). Delta SSM presented excellent accuracy in identifying HVPG responders (AUROC 0.973; 95% CI 0.912–1). The best cut-off for delta SSM to identify responders was -10% (sensitivity 100%, specificity 60%, NPV 100% and PPV 90%).

Conclusions

SSM could be a reliable non-invasive test for the assessment of hemodynamic response to NSBB therapy as primary prophylaxis for HRV. Similar to HVPG, SSM reduction ≥ 10% is able to assess hemodynamic response.

Graphic abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

PH:

Portal hypertension

EV:

Esophageal varices

HVPG:

Hepatic venous gradient pressure

NSBB:

Non-selective β-blockers

HRV:

High-bleeding risk esophageal varices

NITs:

Non-invasive tests

LSM:

Liver stiffness measurement

SSM:

Spleen stiffness measurement

ARFI:

Acoustic radiation forced impulse

TE:

Transient elastography

EGD:

Esophagogastroduodenoscopy

HCC:

Hepatocellular carcinoma

EBL:

Esophageal banding ligation

US:

Ultrasound

EFSUMB:

European Federation of Societies for Ultrasound in Medicine and Biology

WHVP:

Wedged hepatic venous pressure

FHVP:

Free hepatic venous pressure

CSPH:

Clinically significant portal hypertension

IQR:

Inter quartile range

CI:

Confidence interval

NPV:

Negative predictive value

PPV:

Positive predictive value,

MELD:

Model for End-Stage Liver Disease

References

  1. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217–231

    Article  Google Scholar 

  2. de Franchis R, Primignani M. Natural history of portal hypertension in patients with cirrhosis. Clin Liver Dis 2001;5:645–663

    Article  Google Scholar 

  3. Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 2009;6:573–582

    Article  CAS  Google Scholar 

  4. de Franchis R, VI Baveno Faculty. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015;63:743–752

    Article  Google Scholar 

  5. Colecchia A, Marasco G, Taddia M, Montrone L, Eusebi LH, Mandolesi D, et al. Liver and spleen stiffness and other noninvasive methods to assess portal hypertension in cirrhotic patients: a review of the literature. Eur J Gastroenterol Hepatol 2015;27:992–1001

    Article  Google Scholar 

  6. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis

  7. Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007;45:1290–1297

    Article  Google Scholar 

  8. Singh S, Fujii LL, Murad MH, Wang Z, Asrani SK, Ehman RL, et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013;11:1573–1584

    Article  Google Scholar 

  9. Reiberger T, Ferlitsch A, Payer BA, Pinter M, Homoncik M, Peck-Radosavljevic M. Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis. J Gastroenterol 2012;47:561–568

    Article  CAS  Google Scholar 

  10. Colecchia A, Montrone L, Scaioli E, Bacchi-Reggiani ML, Colli A, Casazza G, et al. Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. Gastroenterology 2012;143:646–654

    Article  Google Scholar 

  11. Colecchia A, Colli A, Casazza G, Mandolesi D, Schiumerini R, Reggiani LB, et al. Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: a prospective study. J Hepatol Eur Assoc Study Liver 2014;60:1158–1164

    Google Scholar 

  12. Colecchia A, Ravaioli F, Marasco G, Festi D. Spleen stiffness by ultrasound elastography. Diagnostic Methods Cirrhosis Portal Hypertens 2018

  13. Marasco G, Colecchia A, Colli A, Ravaioli F, Casazza G, Bacchi Reggiani ML, et al. Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection. J Hepatol 2019;70:440–448

    Article  Google Scholar 

  14. Kim HY, So YH, Kim W, Ahn DW, Jung YJ, Woo H, et al. Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices. J Hepatol 2019;70:412–422

    Article  CAS  Google Scholar 

  15. Dietrich CF, Bamber J, Berzigotti A, Bota S, Cantisani V, Castera L, et al. EFSUMB guidelines and recommendations on the clinical use of liver ultrasound elastography, update 2017 (long version). Ultraschall der Medizin 2017;38:e16–e47

    Google Scholar 

  16. Mandorfer M, Reiberger T. Beta blockers and cirrhosis, 2016. Dig Liver Dis 2017;3–10

  17. Zacharias AP, Jeyaraj R, Hobolth L, Bendtsen F, Gluud LL, Morgan MY. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. Cochrane Database Syst Rev 2018;10:11510

    Google Scholar 

  18. Feu F, García-Pagán JC, Bosch J, Luca A, Escorsell A, Rodés J, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995;346:1056–1059

    Article  CAS  Google Scholar 

  19. Ravaioli F, Conti F, Brillanti S, Andreone P, Mazzella G, Buonfiglioli F, et al. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals. Dig Liver Dis 2018;50:573–579

    Article  Google Scholar 

  20. Colecchia A, Ravaioli F, Marasco G, Colli A, Dajti E, Di Biase AR, et al. A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease. J Hepatol 2018;69:308–317

    Article  Google Scholar 

  21. Mandorfer M, Kozbial K, Schwabl P, Chromy D, Semmler G, Stättermayer AF, et al. Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy. Hepatology 2020;71:1023–1036

    Article  CAS  Google Scholar 

  22. Balakrishnan M, Souza F, Munoz C, Augustin S, Loo N, Deng Y, et al. Liver and spleen stiffness measurements by point shear wave elastography via acoustic radiation force impulse: intraobserver and interobserver variability and predictors of variability in a US population. J Ultrasound Med Engl 2016;35:2373–2380

    Article  Google Scholar 

  23. Lin YH, Yeh ML, Huang CI, Yang JF, Liang PC, Huang CF, et al. The performance of acoustic radiation force impulse imaging in predicting liver fibrosis in chronic liver diseases. Kaohsiung J Med Sci 2016;32:362–366

    Article  Google Scholar 

  24. Hernández-Gea V, Procopet B, Giráldez Á, Amitrano L, Villanueva C, Thabut D, et al. Preemptive-TIPS improves outcome in high-risk variceal bleeding: an observational study. Hepatology 2019;69:282–293

    Article  Google Scholar 

  25. Piecha F, Paech D, Sollors J, Seitz H-K, Rössle M, Rausch V, et al. Rapid change of liver stiffness after variceal ligation and TIPS implantation. Am J Physiol Liver Physiol 2018;314:G179–G187187

    Google Scholar 

  26. Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Calleja JL, Aracil C, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet (London, England) 2019;393:1597–1608

    Article  CAS  Google Scholar 

  27. Turco L, Villanueva C, La Mura V, García-Pagán JC, Reiberger T, Genescà J, et al. Lowering portal pressure improves outcomes of patients with cirrhosis, with or without ascites: a meta-analysis. Clin Gastroenterol Hepatol 2020;18(313–327):e6

    Google Scholar 

  28. Reiberger T, Ulbrich G, Ferlitsch A, Payer BA, Schwabl P, Pinter M, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut 2013;62:1634–1641.

    Article  CAS  Google Scholar 

  29. Mandorfer M, Hernández-Gea V, Reiberger T, García-Pagán JC. Hepatic venous pressure gradient response in non-selective beta-blocker treatment—is it worth measuring? Curr Hepatol Rep 2019;18:174–186

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

GM, DF and AC designed the study; GM, ED, FR, DF, AC analyzed and interpreted the data; GM, ED and AC drafted the article. All authors acquired the data, revised the manuscript and approved its final version for publication.

Corresponding author

Correspondence to Giovanni Marasco.

Ethics declarations

Conflict of interest

Giovanni Marasco, Elton Dajti, Federico Ravaioli, Luigina Vanessa Alemanni, Fabiana Capuano, Kamela Gjini, Luigi Colecchia, Giovanni Puppini, Caterina Cusumano, Matteo Renzulli, Rita Golfieri, Davide Festi, Antonio Colecchia declare that they have no conflict of interest.

Informed consent in studies with human subjects

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. Informed consent was obtained from all patients for being included in the study.

Animal studies

This article does not contain any studies with human or animal subjects.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marasco, G., Dajti, E., Ravaioli, F. et al. Spleen stiffness measurement for assessing the response to β-blockers therapy for high-risk esophageal varices patients. Hepatol Int 14, 850–857 (2020). https://doi.org/10.1007/s12072-020-10062-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-020-10062-w

Keywords

Navigation